← Leaderboards
John P Thyfault
Kansas City Va Medical Center
$9,426,648
Attributed
$14,395,666
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,629,191 · 13
VA$0 · 1
By mechanism
P20$12,023,041 · 4
R01$9,052,411 · 4
U01$1,569,053 · 1
T32$707,259 · 1
S10$601,761 · 1
R21$420,750 · 1
Top collaborators
- Steven A Weinman7 shared
- Peter A Crawford6 shared
- P. Darrell Neufer5 shared
- Douglas E Wright4 shared
- Frank W Booth3 shared
- Andrew Lutkewitte3 shared
- Randy Scott Rector3 shared
- Felicia Steger3 shared
Most similar at Kansas City Va Medical Center
Same institution · by research overlap
- Steven A Weinman$15,187,659
Others in their field
Top investigators on “Obesity”
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,827,660
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
ObesityLinkMetabolicMitochondriaMetabolismNon-Insulin-Dependent Diabetes MellitusLiverSedentaryHepaticExerciseResponseChronicPreventAgingPathologyMolecularPredispositionInsulin ResistanceOxidationPlayTherapeutic TargetIn VivoLiver DiseasesMediating
Grant awards (57)
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$2,324,998
P20 · FY2025 · GM
Pilot & Feasibility Program$254,916
P2C · FY2025 · DK · contact PI
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States$216,132
T32 · FY2025 · DK
Dysfunctional adipose tissue's role in hepatic metabolic disease$211,401
P20 · FY2025 · GM
longitudinal assessment of stress and stress-related concepts across a behavioral weight loss intervention$210,975
P20 · FY2025 · GM
Effects of Intermittent Fasting on Glycemic Control in Patients with Diabetes$178,065
P20 · FY2025 · GM
Ovarian function and hepatic mitochondrial quality control in steatosis$0
I01 · FY2025 · VA · contact PI
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$2,324,998
P20 · FY2024 · GM
Ketogenic oscillations and neurometabolic healthspan$385,500
R01 · FY2024 · AG
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$280,142
P20 · FY2024 · GM
Effects of Intermittent Fasting on Glycemic Control in Patients with Diabetes$254,508
P20 · FY2024 · GM
Dysfunctional adipose tissue's role in hepatic metabolic disease$234,811
P20 · FY2024 · GM
longitudinal assessment of stress and stress-related concepts across a behavioral weight loss intervention$232,275
P20 · FY2024 · GM
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States$170,413
T32 · FY2024 · DK
Ovarian function and hepatic mitochondrial quality control in steatosis$0
I01 · FY2024 · VA · contact PI
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$2,320,048
P20 · FY2023 · GM
Ketogenic oscillations and neurometabolic healthspan$385,500
R01 · FY2023 · AG
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$317,437
P20 · FY2023 · GM
Effects of Intermittent Fasting on Glycemic Control in Patients with Diabetes$234,981
P20 · FY2023 · GM
Dysfunctional adipose tissue's role in hepatic metabolic disease$232,500
P20 · FY2023 · GM
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States$215,166
T32 · FY2023 · DK
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$50,500
P20 · FY2023 · GM
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis$0
I01 · FY2023 · VA · contact PI
Kansas Center for Metabolism and Obesity REsearch (KC-MORE)$2,615,402
P20 · FY2022 · GM
Molecular Transducers of Physical Activity: Liver Adaptations Drive Brain Benefits$516,685
U01 · FY2022 · AG
Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.$463,020
R01 · FY2022 · DK · contact PI
Ketogenic oscillations and neurometabolic healthspan$385,500
R01 · FY2022 · AG
Translating Obesity, Metabolic Dysfunction and Comorbid Disease States$105,548
T32 · FY2022 · DK
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis$0
I01 · FY2022 · VA · contact PI
Statins: Mitochondrial Function and Aerobic Capacity$558,492
R01 · FY2021 · AR · contact PI
Molecular Transducers of Physical Activity: Liver Adaptations Drive Brain Benefits$516,059
U01 · FY2021 · AG
Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.$465,985
R01 · FY2021 · DK · contact PI
Ketogenic oscillations and neurometabolic healthspan$385,375
R01 · FY2021 · AG
Ketogenic Oscillations and Neurometabolic Healthspan$385,204
R01 · FY2021 · AG
Divergence in Aerobic Capacity Drives Liver and Brain Health$377,622
R01 · FY2021 · DK · contact PI
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis$0
I01 · FY2021 · VA · contact PI
Statins: Mitochondrial Function and Aerobic Capacity$607,983
R01 · FY2020 · AR · contact PI
Metabolic Phenotyping Cluster$601,761
S10 · FY2020 · OD · contact PI
Molecular Transducers of Physical Activity: Liver Adaptations Drive Brain Benefits$536,309
U01 · FY2020 · AG
Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.$466,270
R01 · FY2020 · DK · contact PI
Ketogenic oscillations and neurometabolic healthspan$397,500
R01 · FY2020 · AG
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosis$0
I01 · FY2020 · VA · contact PI
Statins: Mitochondrial Function and Aerobic Capacity$617,659
R01 · FY2019 · AR · contact PI
Aerobic Fitness, Mitochondrial Function, and Fatty Liver Disease.$470,701
R01 · FY2019 · DK · contact PI
Statins: Mitochondrial Function and Aerobic Capacity$623,558
R01 · FY2018 · AR · contact PI
Skeletal muscle mitochondrial abnormalities in Alzheimer's Disease$191,250
R21 · FY2018 · AG · contact PI
Mitochondrial mitophagy in the development and treatment of NAFLD$0
I01 · FY2018 · VA · contact PI
Statins: Mitochondrial Function and Aerobic Capacity$616,919
R01 · FY2017 · AR · contact PI
Skeletal muscle mitochondrial abnormalities in Alzheimer's Disease$229,500
R21 · FY2017 · AG · contact PI
Mitochondrial mitophagy in the development and treatment of NAFLD$0
I01 · FY2017 · VA · contact PI
Mitochondrial mitophagy in the development and treatment of NAFLD$0
I01 · FY2016 · VA · contact PI
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease$283,125
R01 · FY2015 · DK · contact PI
Mitochondrial mitophagy in the development and treatment of NAFLD$0
I01 · FY2015 · VA · contact PI
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease$276,338
R01 · FY2014 · DK · contact PI
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease$266,666
R01 · FY2013 · DK · contact PI
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease$276,338
R01 · FY2012 · DK · contact PI
Aerobic fitness, mitochondrial dysfunction, and fatty liver disease$357,156
R01 · FY2011 · DK · contact PI